stock-detail (LPTN)

Oncology Corporate Profile

Company Description

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
sonepcizumabanti-sphingosine1-phosphate-mAB)Renal cell carcinoma (RCC)II

Recent News Headlines

Apollo Endosurgery Completes Merger with Lpath; Initiates Trading on NASDAQ as ‘APEN’

12/29/2016 09:03 pm

[Business Wire] - Apollo Endosurgery, Inc. , a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that it has completed its merger transaction with Lpath, Inc.

LPATH, INC Financials

11/18/2016 06:00 pm

Apollo Endosurgery and Lpath Sign Merger Agreement

9/17/2016 09:05 am

[at noodls] - www.apolloendo.com. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version.

Apollo Endosurgery and Lpath Sign Merger Agreement

9/8/2016 08:01 pm

[at noodls] - www.apolloendo.com. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version.

Apollo Endosurgery and Lpath Sign Merger Agreement

9/8/2016 08:00 pm

[PR Newswire] - AUSTIN, Texas and SAN DIEGO, Sept. 8, 2016 /PRNewswire/ -- Lpath, Inc. (LPTN) and Apollo Endosurgery, Inc. today announced that they have entered into a definitive merger agreement under which the security holders of Apollo would become the majority owners of Lpath. Under terms of the agreement, Lpath will issue new shares of its common stock or rights to acquire its common stock to Apollo security holders.

Lpath Awarded Department of Defense Grant for Traumatic Brain Injury Pain Study

6/20/2016 12:02 pm

[at noodls] - SAN DIEGO, June 20, 2016 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been awarded a $1.45 million two-year grant by the Defense Medical ...

Lpath Awarded Department of Defense Grant for Traumatic Brain Injury Pain Study

6/20/2016 12:00 pm

[PR Newswire] - SAN DIEGO, June 20, 2016 /PRNewswire/ -- Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program (DMRDP), an agency of the U.S. Department of Defense (DoD). This grant will support the study of Lpathomab for the treatment of neuropathic pain associated with traumatic brain injury (TBI). Lpath is working with Professor David Yeomans, Ph.D. of Stanford University's Department of Anesthesia on this project and he will serve as co-principal investigator.

Lpath Announces 1-for-14 Reverse Stock Split

6/9/2016 12:02 pm

[at noodls] - SAN DIEGO, June 9, 2016 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN) announced a 1-for-14 reverse split of the company's issued and outstanding common stock, effective as of 5:00 p.m. EDT on June 10, 2016. ...